Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GIPR | P48546 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255802 | 0.91 | MEN1 (0.48) | KMT2AMEN1CNR1ALDH1A1GCGR | |
| SCHEMBL13749330 | 0.90 | GCGR (0.44) | KMT2AMEN1MAPTCNR1ALDH1A1 | |
| SCHEMBL2667291 | 0.85 | GCGR (0.59) | GCGRGIPRCYP2C9 | |
| SCHEMBL2253874 | 0.82 | GCGR (0.42) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL2667296 | 0.82 | GCGR (0.57) | ALDH1A1LMNAGCGRGIPRGAA | |
| SCHEMBL12360426 | 0.82 | GCGR (0.59) | GCGRGIPRCYP2C9 | |
| SCHEMBL3386433 | 0.81 | MEN1 (0.48) | KMT2AMEN1GCGRPOLBGIPR | |
| SCHEMBL2250997 | 0.81 | GCGR (0.45) | KMT2AMEN1KDM4EGCGRPOLB | |
| SCHEMBL13003304 | 0.81 | GCGR (0.53) | GCGRGIPRCYP2C9 | |
| SCHEMBL2254697 | 0.80 | MAPT (0.47) | KMT2AMEN1MAPTGCGRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989475-B2 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1590336-B1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090215825-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2009-08-27 | — | — | US | disclosed |
| US-7572922-B2 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060084681-A1 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215825-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GLP1R, GCGR, GPR119 | KMT2A 3734/4885MEN1 2999/4885MAPT 4651/4885 |
| US-20060084681-A1 | Substituted pyrazoles, compositions containing such compounds and methods of use | GLP1R, GCGR, GPR119 | KMT2A 3734/4885MEN1 2999/4885MAPT 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.